1. Home
  2. NE vs CELC Comparison

NE vs CELC Comparison

Compare NE & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Noble Corporation plc A

NE

Noble Corporation plc A

HOLD

Current Price

$46.77

Market Cap

8.0B

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$89.32

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NE
CELC
Founded
1985
2011
Country
United States
United States
Employees
4500
N/A
Industry
Other Specialty Stores
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
7.0B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
NE
CELC
Price
$46.77
$89.32
Analyst Decision
Buy
Strong Buy
Analyst Count
7
9
Target Price
$46.00
$112.56
AVG Volume (30 Days)
1.2M
1.2M
Earning Date
04-26-2026
05-13-2026
Dividend Yield
3.98%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$9.18
$720.19
P/E Ratio
$32.79
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.24
$11.54
52 Week High
$54.98
$151.02

Technical Indicators

Market Signals
Indicator
NE
CELC
Relative Strength Index (RSI) 37.29 25.86
Support Level $45.44 $45.64
Resistance Level $47.44 $115.19
Average True Range (ATR) 1.59 9.51
MACD -0.73 -5.33
Stochastic Oscillator 8.06 8.98

Price Performance

Historical Comparison
NE
CELC

About NE Noble Corporation plc A

Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units. The company focuses on a high-specification fleet of floating and jackup rigs and on deploying its drilling rigs in oil and gas basins around the world. The mobile offshore drilling units comprising the offshore rig fleet operate in international markets for contract drilling services and are often redeployed to different regions due to changing customer demand, which consists mainly of large, integrated, independent, and government-owned or controlled oil and gas companies throughout the world.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: